Table 3.

Recurrence-Free Survival for Patients Undergoing Adjuvant Mitomycin C

Variable	N	Recurrence	RFS rate at 3 years (95% CI)	RFS rate at 5 years(95% CI)
Overall	28	11	0.6 (0.42, 0.86)	0.36 (0.16, 0.80)
Tumor grade
Low	21	9	0.62 (0.42, 0.91)	0.31 (0.11, 0.89)
High	7	2	0.6 (0.29, 1)
Focality
Solitary	9	6	0.73 (0.52, 1)
Multifocal	9	5	0.4 (0.17, 0.94)	0.4 (0.17, 0.94)
Renal function at diagnosis
eGFR ≥60	15	4	0.67 (0.43, 1)	0.67 (0.43, 1)
eGFR <60	13	7	0.53 (0.30, 0.95)
Treatment indication
Elective	13	3
Imperative	13	7	0.50 (0.27, 0.89)	0.37 (0.16, 0.84)
Palliative	2	1	1 (1, 1)
Tobacco history
Nonsmoker	12	5	0.509 (0.27, 0.95)
Smoker	16	6	0.69 (0.44, 1)	0.33 (0.12, 0.97)
Delivery method
Ureteral catheter	19	9	50% (0.25,1)	0.26 (0.08, 0.76)
Nephrostomy tube	9	2	63% (0.410, 0.99)	0.40 (0.23, 0.90)
Lynch syndrome
Negative	23	8	0.62 (0.42, 0.93)	0.45 (0.09, 0.91)
Positive	5	3	0.56 (0.28, 1)	0.2 (0.10, 0.78)

CI = confidence interval; eGFR = estimated GFR; RFS = recurrence-free survival.